Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan

Background and Aim Ustekinumab, a human anti‐interleukin‐12/23 monoclonal antibody, has been approved in Japan for the treatment of Crohn's disease. Here, we report the findings from an 8‐week interim analysis of post‐marketing surveillance to evaluate the safety and effectiveness of ustekinumab in Japanese patients with Crohn's disease. Methods Patients initiating ustekinumab treatment were prospectively evaluated from May 2017 to June 2020 at...